Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Mayo Clinic: 2-drug Combination May… >
Mayo Clinic: 2-drug Combination May Slow Deadly Thyroid Cancer

Published: January 8, 2013.
By Mayo Clinic
http://www.mayoclinic.org/news

ROCHESTER, Minn. -- A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs together resulted in greater anti-cancer activity in ATC than either drug alone, says lead researcher Keith Bible, M.D., Ph.D., a Mayo Clinic oncologist.

Anaplastic thyroid cancer is a rare but devastating form of thyroid cancer that typically strikes men and women in their 60s and 70s. It is very aggressive, with a median survival of only about 5 months from time of diagnosis. Only 20 percent of patients survive a year beyond diagnosis, and it has historically been found to be resistant to most therapies.

Pazopanib, a kinase-inhibitor that interferes with the growth of cancer cells, is already approved by the Food and Drug Administration (FDA) to treat renal cancer tumors. Paclitaxel is an FDA-approved chemotherapy drug that disrupts the machinery involved in cell division.

Researchers studied anaplastic thyroid cancer cells and tumors in cell culture and in animal models. Human ATC cells were readily killed, and ATC tumors implanted into mice were 50 percent smaller when treated with the combination in comparison to the response to treatment with either drug alone. Pilot therapy of one patient with metastatic anaplastic thyroid cancer using the combination also resulted in marked tumor shrinkage lasting over six months. "This was a highly unexpected finding for this type of aggressive tumor, which often can double in size in a matter of days," Dr. Bible says.

In previous studies, pazopanib alone was found not effective in the treatment of anaplastic thyroid cancer. Paclitaxel was added to address the aggressiveness of anaplastic thyroid cancer tumors and bolster anti-cancer effects. The team investigated how the two drugs might complement each other.

Monitoring cancer cells multiply in time-lapse video under a microscope, researchers noted that the drug combination resulted in abnormal cell division and an increase in ATC cell death. Although pazopanib had not been known to specifically affect cell division, researchers speculated that the drug might have another unrecognized molecular target within cancer cells.

"We ended up learning that pazopanib also happens to inhibit a protein involved in cell division known as aurora A; this property seems to be involved in producing enhanced effects when pazopanib is combined with paclitaxel," Dr. Bible says. "This finding suggests that the combination may also be useful in treating other cancers, such as breast cancer, in which aurora A is sometimes found to be present in elevated amounts, as it is in ATC," Dr. Bible says.

The results also prompted an ongoing randomized multicenter clinical trial, led by Mayo Clinic and Memorial Sloan-Kettering Cancer Center and administered through the Radiation Therapy Oncology Group, testing the two-drug combination when added to radiation therapy in the initial treatment of patients with anaplastic thyroid cancer.

"This important next step is designed to determine whether the combination of drugs will improve ATC patient survival compared to paclitaxel alone," Dr. Bible says.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the ScienceNewsline.
Related »

Months 
11/15/13 
Multicenter Study Underscored the Need of a Uniform Approach to the Treatment of BCa
By European Association of Urology
Arnhem, The Netherlands - New study, involving eight Italian research centres, concluded that an aligned approach to the treatment of advanced bladder cancer is much needed, while confirming previously …
Asian 
6/2/11 
Asian Lung Cancer Patient Survival Exceeds Caucasians' on Multiple Regimens
By International Association for the Study of Lung Cancer
Asian non-small cell lung cancer (NSCLC) patients survive longer than Caucasians no matter how many drugs are given in a first-line setting, and the effect was apparent both before …
Sunitinib 
8/21/13 
Pazopanib Shows Better Quality-of-life in Advanced Kidney Cancer
By Dana-Farber Cancer Institute
BOSTON -- Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial …
Cancer 
2/8/13 
★ 
Study Drug Is First to Help Patients with Recurrent Low-grade Ovarian Cancer
By University of Texas M. D. Anderson Cancer Center
HOUSTON - Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails. …
Months 
10/5/10 
★ 
Vaccine Extends Glioblastoma Patients' Survival in Phase II Trial
By University of Texas M. D. Anderson Cancer Center
HOUSTON - A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of …
Therapeutic 
7/25/13 
Researchers Find Potential New Target to Treat Malignant Pleural Mesothelioma
By International Association for the Study of Lung Cancer
DENVER – Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis. …
More » 

Most Popular - Medicine »
MARIJUANA »
Casual Marijuana Use Linked to Brain Abnormalities in Students
CHICAGO --- Young adults who used marijuana only recreationally showed significant abnormalities in two key brain regions that are important in emotion and motivation, scientists report. The study was …
IMMUNE »
The Immune System's Redesigned Role in Fighting Cancerous Tumors
LOS ANGELES (March 11, 2014) – Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid tumors in laboratory mice using a novel combination of two targeted agents. …
MILK »
The Surprising Consequences of Banning Chocolate Milk
SURVIVORS »
New Research Shows People Are Thinking About Their Health Early in the Week
San Diego, Calif. (April 18, 2014) ― A new study in the American Journal of Preventive Medicine analyzing weekly patterns in health-related Google searches reveals a recurring pattern that …
BULLYING »
Impact of Childhood Bullying Still Evident After 40 Years
The negative social, physical and mental health effects of childhood bullying are still evident nearly 40 years later, according to new research by King's College London. The study is …
ScienceNewsline  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese
The selection and placement of stories are determined automatically by a computer program. All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.